XML 38 R28.htm IDEA: XBRL DOCUMENT
v3.21.2

REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2021
Concentration Risk And Geographic Information [Abstract] |
Schedule of Total Revenues from External Customers and Collaborative Partners by Geographic Region | The following table disaggregates Total Revenues from external customers and collaborative partners by geographic region. Net product revenues by geographic region are based on patient location for the Company’s commercial products, except for Aldurazyme, which is sold exclusively to Sanofi Genzyme (Genzyme) who markets and sells Aldurazyme worldwide. Aldurazyme revenues earned by the Company are included in the U.S. region as the transactions are with Genzyme, whose headquarters is located in the U.S.
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2021 |  | 2020 |  | 2021 |  | 2020
Total revenues by geographic region: |  |  |  |  |  |  |
United States | $ | 196,239 |  |  | $ | 252,948 |  |  | $ | 608,670 |  |  | $ | 729,672 |
Europe | 115,497 |  |  | 121,158 |  |  | 450,016 |  |  | 375,453 |
Latin America | 38,958 |  |  | 44,064 |  |  | 140,911 |  |  | 141,852 |
Rest of world | 58,048 |  |  | 58,614 |  |  | 196,868 |  |  | 161,361 |
Total revenues | $ | 408,742 |  |  | $ | 476,784 |  |  | $ | 1,396,465 |  |  | $ | 1,408,338 |
Schedule of Net Product Revenues by Product | The following table disaggregates total Net Product Revenues by product.
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2021 |  | 2020 |  | 2021 |  | 2020
Net product revenues by product: |  |  |  |  |  |  |
Vimizim | $ | 136,744 |  |  | $ | 147,891 |  |  | $ | 466,697 |  |  | $ | 401,789 |
Naglazyme | 71,172 |  |  | 76,323 |  |  | 297,321 |  |  | 271,585 |
Kuvan | 67,687 |  |  | 123,993 |  |  | 217,257 |  |  | 368,604 |
Palynziq | 60,729 |  |  | 46,092 |  |  | 173,702 |  |  | 121,354 |
Brineura | 32,984 |  |  | 25,455 |  |  | 90,641 |  |  | 75,223 |
Voxzogo | 144 |  |  | — |  |  | 144 |  |  | — |
Firdapse | — |  |  | — |  |  | — |  |  | 1,316 |
Total net product revenues marketed by the Company | $ | 369,460 |  |  | $ | 419,754 |  |  | $ | 1,245,762 |  |  | $ | 1,239,871 |
Aldurazyme net product revenues marketed by Genzyme | 24,380 |  |  | 40,987 |  |  | $ | 102,517 |  |  | $ | 128,945 |
Total net product revenues | $ | 393,840 |  |  | $ | 460,741 |  |  | $ | 1,348,279 |  |  | $ | 1,368,816 |
Schedule of Total Net Product Revenues Based on Patient Location | The table below disaggregates total Net Product Revenues based on patient location for products sold directly by the Company, and global sales of Aldurazyme, which is marketed by Genzyme.
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2021 |  | 2020 |  | 2021 |  | 2020
United States | $ | 166,554 |  |  | $ | 203,892 |  |  | $ | 491,028 |  |  | $ | 582,734 |
Europe | 108,568 |  |  | 115,548 |  |  | 424,144 |  |  | 360,718 |
Latin America | 38,958 |  |  | 44,064 |  |  | 140,911 |  |  | 141,852 |
Rest of world | 55,380 |  |  | 56,250 |  |  | 189,679 |  |  | 154,567 |
Total net product revenues marketed by the Company | $ | 369,460 |  |  | $ | 419,754 |  |  | $ | 1,245,762 |  |  | $ | 1,239,871 |
Aldurazyme net product revenues marketed by Genzyme | 24,380 |  |  | 40,987 |  |  | 102,517 |  |  | 128,945 |
Total net product revenues | $ | 393,840 |  |  | $ | 460,741 |  |  | $ | 1,348,279 |  |  | $ | 1,368,816 |
Schedule of Net Product Revenue Concentrations Attributed to Largest Customers | The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented.
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2021 |  | 2020 |  | 2021 |  | 2020
Customer A | 20 | % |  | 16 | % |  | 17 | % |  | 15 | %
Customer B | 16 | % |  | 14 | % |  | 14 | % |  | 14 | %
Customer C | 11 | % |  | 11 | % |  | 10 | % |  | 12 | %
Total | 47 | % |  | 41 | % |  | 41 | % |  | 41 | %

X
- Definition Concentration risk and geographic information. + References No definition available. + Details
Name: | bmrn_ConcentrationRiskAndGeographicInformationAbstract
Namespace Prefix: | bmrn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph a -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 + Details
Name: | us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration